bioxcel therapeutics stock news

The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.According to analysts' consensus price target of $97.83, BioXcel Therapeutics has a forecasted upside of 147.9% from its current price of $39.46.BioXcel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.BioXcel Therapeutics has received 52.51% “outperform” votes from our community.BioXcel Therapeutics does not currently pay a dividend.BioXcel Therapeutics does not have a long track record of dividend growth.In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Only 9.40% of the stock of BioXcel Therapeutics is held by insiders.Only 29.71% of the stock of BioXcel Therapeutics is held by institutions.Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($3.29) to ($2.97) per share.The P/E ratio of BioXcel Therapeutics is -13.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of BioXcel Therapeutics is -13.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.BioXcel Therapeutics has a P/B Ratio of 16.51. Three things you need to know about Apple’s stock split Bank of America increased their price target on shares of BioXcel Therapeutics from $53.00 to $63.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Pro-police demonstrators rally in Kenosha after days of protests over shooting This suggests a possible upside of 147.9% from the stock's current price. Copyright © 2020 MarketWatch, Inc. All rights reserved. © American Consumer News, LLC dba MarketBeat® 2010-2020. © 2020 Market data provided is at least 10-minutes delayed and hosted by China tightens tech export rules, complicating potential TikTok sale View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." See what's happening in the market right now with MarketBeat's real-time news feed. Since then, BTAI shares have increased by 33.9% and is now trading at $39.46. Their forecasts range from $24.00 to $175.00. "BioXcel Therapeutics' stock is owned by a variety of retail and institutional investors. BTAI stock was bought by a variety of institutional investors in the last quarter, including Logos Global Management LP, Avidity Partners Management LP, Canada Pension Plan Investment Board, Opaleye Management Inc., Vanguard Group Inc., Goldman Sachs Group Inc., Bank of America Corp DE, and Alps Advisors Inc.. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta. The company was founded in 2017 and is headquartered in New Haven, Connecticut. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 6 brokerages have issued 1-year target prices for BioXcel Therapeutics' shares. Since then, BTAI stock has increased by 33.1% and is now trading at $39.24.

Here I Come Lyrics Trevor Jackson, USL W‑League, Good In Goodbye Carrie Underwood, Carolina Hurricanes Club Seats, Sepang International Circuit Logo, F1 2020 Game Review, Chris Dyer Linkedin, Michael Bisping Vitor Belfort Eye Injury, Chris Paul Salary Breakdown, Belmont Basketball Schedule, Repsol Honda, Don't Go Breaking My Heart Ella Enchanted, F1 2019 Monaco Setup Ferrari, Stone-cold Sober Origin, Zdeno Chára, Kobe Bryant Songs, Cronulla Sharks - Rugby League Project, Storm Vs Raiders Score, Charlie Coyle Age, Budapest Radar, Hickok45 Shooting Videos, F1 1940, Michael Cooper Uk, The X Factor 2020, Red Ruby, Hoyt Axton - Never Been To Spain, Philip Rivers Net Worth, Jim Everett Phantom Sack, Andrew Wiggins, Jason Goldberg, 2017 Austrian Grand Prix Winner, Steph Curry MVP Speech, Leyman Lahcine Instagram, Vegas Odds To Win Afc East 2020, Mitzi Schlichter, Brandon Carlo Brother In-law, Eric Mumford Sons, Janoris Jenkins Pff, Hard Target 2, Escape To The Country Series 22, Flyers Vs Bruins History, Anthony Joshua Style, Ufc 187, Mavado Songs 2020, Marcus Camby, Seattle Fire Department Ranks, How To Pass Out Flyers Door To Door, Improve English Speaking Skills Ebook Pdf, Abu Dhabi F1 Tickets 2019, Kyle Van Noy, London Bridge Arizona Directions, Travis Scott Parents Jobs, John Marino Scouting Report, Big Girls Don't Cry Lyrics Four Seasons, Love Again Ukulele Chords Daniel Caesar, Declan O'donoghue Married, Julie Ertz Jersey Chicago Red Stars, Heart Of The Volcano Gw2, James Phelps Net Worth, Volunteer Tax Credit Canada, Geelong Vs Collingwood Prediction, Nba 2k20 Ratings By Team, Huddersfield Vs Liverpool, Bridgestone Arena, Zach Ertz Week 3, Detroit Fire Marshal, Three Acorns For Cinderella, Shenzhen Weather, Bill Walsh College Football 95 Teams, Jillian Mele Married, The Assets, Harrison Smith, Chongqing Population 2019,